Christopher M Hovens

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2686790/publications.pdf

Version: 2024-02-01

123 papers

13,354 citations

43 h-index 25787 108 g-index

124 all docs

124 docs citations

times ranked

124

22917 citing authors

#	Article	IF	CITATIONS
1	The Molecular Taxonomy of Primary Prostate Cancer. Cell, 2015, 163, 1011-1025.	28.9	2,435
2	An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. Cell, 2018, 173, 400-416.e11.	28.9	2,277
3	Genomic and Functional Approaches to Understanding Cancer Aneuploidy. Cancer Cell, 2018, 33, 676-689.e3.	16.8	750
4	Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images. Cell Reports, 2018, 23, 181-193.e7.	6.4	683
5	Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients. Cancer Cell, 2018, 34, 211-224.e6.	16.8	623
6	Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. Cell Systems, 2018, 6, 271-281.e7.	6.2	605
7	IncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic IncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer. Cancer Cell, 2018, 33, 706-720.e9.	16.8	400
8	Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types. Cell Reports, 2018, 23, 282-296.e4.	6.4	333
9	Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer. Nature Communications, 2015, 6, 6605.	12.8	312
10	A B-cell coactivator of octamer-binding transcription factors. Nature, 1995, 373, 360-362.	27.8	307
11	Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas. Cell Systems, 2018, 6, 282-300.e2.	6.2	284
12	A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples. Cell, 2018, 173, 386-399.e12.	28.9	228
13	Pan-Cancer Analysis of IncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context. Cell Reports, 2018, 23, 297-312.e12.	6.4	205
14	The Junction-associated Protein AF-6 Interacts and Clusters with Specific Eph Receptor Tyrosine Kinases at Specialized Sites of Cell–Cell Contact in the Brain. Journal of Cell Biology, 1999, 144, 361-371.	5 . 2	187
15	Ryk-deficient mice exhibit craniofacial defects associated with perturbed Eph receptor crosstalk. Nature Genetics, 2000, 25, 414-418.	21.4	157
16	Sodium selenate specifically activates PP2A phosphatase, dephosphorylates tau and reverses memory deficits in an Alzheimer's disease model. Journal of Clinical Neuroscience, 2010, 17, 1025-1033.	1.5	134
17	Sodium selenate reduces hyperphosphorylated tau and improves outcomes after traumatic brain injury. Brain, 2015, 138, 1297-1313.	7.6	131
18	Reducing the risk of false discovery enabling identification of biologically significant genome-wide methylation status using the HumanMethylation450 array. BMC Genomics, 2014, 15, 51.	2.8	126

#	Article	IF	CITATIONS
19	RYK, a receptor tyrosine kinase-related molecule with unusual kinase domain motifs Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 11818-11822.	7.1	123
20	Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas. Cell Reports, 2018, 23, 172-180.e3.	6.4	119
21	Upgrade in Gleason score between prostate biopsies and pathology following radical prostatectomy significantly impacts upon the risk of biochemical recurrence. BJU International, 2011, 108, E202-E210.	2.5	103
22	Sodium selenate retards epileptogenesis in acquired epilepsy models reversing changes in protein phosphatase 2A and hyperphosphorylated tau. Brain, 2016, 139, 1919-1938.	7.6	100
23	Tumour angiogenesis: Its mechanism and therapeutic implications in malignant gliomas. Journal of Clinical Neuroscience, 2009, 16, 1119-1130.	1.5	98
24	The application of the polymerase chain reaction to cloning members of the protein tyrosine kinase family. Gene, 1989, 85, 67-74.	2.2	86
25	Mutagenesis and selection of PDZ domains that bind new protein targets. Nature Biotechnology, 1999, 17, 170-175.	17.5	84
26	Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types. Cell Reports, 2018, 23, 213-226.e3.	6.4	83
27	Targeting malignant glioma survival signalling to improve clinical outcomes. Journal of Clinical Neuroscience, 2007, 14, 301-308.	1.5	82
28	An In Vitro Assay of Î ² -Galactosidase from Yeast. BioTechniques, 1996, 20, 960-962.	1.8	81
29	A urinary microRNA signature can predict the presence of bladder urothelial carcinoma in patients undergoing surveillance. British Journal of Cancer, 2016, 114, 454-462.	6.4	78
30	Targeting Stat3 and Smad7 to restore TGF- \hat{l}^2 cytostatic regulation of tumor cells in vitro and in vivo. Oncogene, 2013, 32, 2433-2441.	5.9	72
31	Targeting hyperphosphorylated tau with sodium selenate suppresses seizures in rodent models. Neurobiology of Disease, 2012, 45, 897-901.	4.4	70
32	Supranutritional Sodium Selenate Supplementation Delivers Selenium to the Central Nervous System: Results from a Randomized Controlled Pilot Trial in Alzheimer's Disease. Neurotherapeutics, 2019, 16, 192-202.	4.4	69
33	Underestimation of Gleason score at prostate biopsy reflects sampling error in lower volume tumours. BJU International, 2012, 109, 660-664.	2.5	66
34	The ability of prostateâ€specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume. BJU International, 2012, 110, 36-42.	2.5	61
35	The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited. European Urology, 2021, 80, 632-640.	1.9	61
36	Sodium selenate, a protein phosphatase 2A activator, mitigates hyperphosphorylated tau and improves repeated mild traumatic brain injury outcomes. Neuropharmacology, 2016, 108, 382-393.	4.1	60

#	Article	IF	CITATIONS
37	Prostate cancer cellâ€intrinsic interferon signaling regulates dormancy and metastatic outgrowth in bone. EMBO Reports, 2020, 21, e50162.	4.5	58
38	Regulation of glycogen synthase kinase-3 beta (GSK-3 \hat{l}^2) by the Akt pathway in gliomas. Journal of Clinical Neuroscience, 2012, 19, 1558-1563.	1.5	55
39	Two versatile eukaryotic expression vectors permitting epitope tagging, radiolabelling and nuclear localisation of expressed proteins. Gene, 1996, 168, 165-167.	2.2	53
40	A Phase IIa Randomized Control Trial ofÂVEL015 (Sodium Selenate) inÂMild-Moderate Alzheimer's Disease. Journal of Alzheimer's Disease, 2016, 54, 223-232.	2.6	53
41	Open-label, phase I dose-escalation study of sodium selenate, a novel activator of PP2A, in patients with castration-resistant prostate cancer. British Journal of Cancer, 2010, 103, 462-468.	6.4	48
42	Repair mechanisms help glioblastoma resist treatment. Journal of Clinical Neuroscience, 2015, 22, 14-20.	1.5	48
43	Paraneoplastic syndromes in prostate cancer. Nature Reviews Urology, 2010, 7, 681-692.	3.8	46
44	Snail expression is an independent predictor of tumor recurrence in superficial bladder cancers. Urologic Oncology: Seminars and Original Investigations, 2010, 28, 591-596.	1.6	46
45	<i>VEGF</i> Polymorphisms are Associated With an Increasing Risk of Developing Renal Cell Carcinoma. Journal of Urology, 2010, 184, 1273-1278.	0.4	46
46	Hyperphosphorylated Tau is Implicated in Acquired Epilepsy and Neuropsychiatric Comorbidities. Molecular Neurobiology, 2014, 49, 1532-1539.	4.0	46
47	Curated MicroRNAs in Urine and Blood Fail to Validate as Predictive Biomarkers for High-Risk Prostate Cancer. PLoS ONE, 2014, 9, e91729.	2.5	43
48	Canonical Androstenedione Reduction Is the Predominant Source of Signaling Androgens in Hormone-Refractory Prostate Cancer. Clinical Cancer Research, 2014, 20, 5547-5557.	7.0	43
49	Distinct requirements for the Sprouty domain for functional activity of Spred proteins. Biochemical Journal, 2005, 388, 445-454.	3.7	41
50	Error rates in a clinical data repository: lessons from the transition to electronic data transferâ€"a descriptive study. BMJ Open, 2013, 3, e002406.	1.9	40
51	Genetics of glioblastoma multiforme: mitogenic signaling and cell cycle pathways converge. Journal of Clinical Neuroscience, 2005, 12, 1-5.	1.5	38
52	Gene-based urinary biomarkers for bladder cancer: An unfulfilled promise?. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 48.e9-48.e17.	1.6	38
53	Glycogen synthase kinase- $3\hat{l}^2$ (GSK- $3\hat{l}^2$) and its dysregulation in glioblastoma multiforme. Journal of Clinical Neuroscience, 2013, 20, 1185-1192.	1.5	36
54	Detection of ctDNA in plasma of patients with clinically localised prostate cancer is associated with rapid disease progression. Genome Medicine, 2020, 12, 72.	8.2	35

#	Article	IF	Citations
55	How Subclonal Modeling Is Changing the Metastatic Paradigm. Clinical Cancer Research, 2017, 23, 630-635.	7.0	34
56	Androgen synthesis in prostate cancer: do all roads lead to Rome?. Nature Reviews Urology, 2017, 14, 49-58.	3.8	34
57	Inferring structural variant cancer cell fraction. Nature Communications, 2020, 11, 730.	12.8	33
58	Cell quiescence correlates with enhanced glioblastoma cell invasion and cytotoxic resistance. Experimental Cell Research, 2019, 374, 353-364.	2.6	31
59	Accelerated kindling epileptogenesis in Tg4510 tau transgenic mice, but not in tau knockout mice. Epilepsia, 2017, 58, e136-e141.	5.1	30
60	Positive surgical margins are a risk factor for significant biochemical recurrence only in intermediateâ€risk disease. BJU International, 2012, 110, 821-827.	2.5	28
61	Molecular Pathways: Targeting DNA Repair Pathway Defects Enriched in Metastasis. Clinical Cancer Research, 2016, 22, 3132-3137.	7.0	28
62	Mitochondrial genome variation and prostate cancer: a review of the mutational landscape and application to clinical management. Oncotarget, 2017, 8, 71342-71357.	1.8	28
63	AF6/sâ€afadin is a dual residency protein and localizes to a novel subnuclear compartment. Journal of Cellular Physiology, 2007, 210, 212-223.	4.1	27
64	Prostate tumour volume is an independent predictor of early biochemical recurrence in a high risk radical prostatectomy subgroup. Pathology, 2011, 43, 138-142.	0.6	26
65	What Is Oligometastatic Prostate Cancer?. European Urology Focus, 2019, 5, 159-161.	3.1	24
66	The tumour suppressor protein NF2/merlin:the puzzle continues. Journal of Clinical Neuroscience, 2001, 8, 4-7.	1.5	23
67	International multicentre study examining selection criteria for active surveillance in men undergoing radical prostatectomy. British Journal of Cancer, 2012, 107, 1467-1473.	6.4	23
68	Circulating endothelial cells as biomarkers of prostate cancer. Nature Reviews Urology, 2008, 5, 445-454.	1.4	22
69	Expression of the adaptor protein Tks5 in human cancer: Prognostic potential. Oncology Reports, 2014, 32, 989-1002.	2.6	22
70	Useful Vectors for the Two-Hybrid System in Mammalian Cells. BioTechniques, 1997, 23, 396-402.	1.8	21
71	Does perineural invasion in a radical prostatectomy specimen predict biochemical recurrence in men with prostate cancer?. Canadian Urological Association Journal, 2015, 9, 252.	0.6	21
72	Comparing nodal versus bony metastatic spread using tumour phylogenies. Scientific Reports, 2016, 6, 33918.	3.3	19

#	Article	IF	CITATIONS
73	Periprostatic fat tissue transcriptome reveals a signature diagnostic for high-risk prostate cancer. Endocrine-Related Cancer, 2018, 25, 569-581.	3.1	19
74	Levels of a subpopulation of platelets, but not circulating endothelial cells, predict early treatment failure in prostate cancer patients after prostatectomy. British Journal of Cancer, 2012, 107, 1564-1573.	6.4	17
75	Presence or absence of a positive pathological margin outperforms any other marginâ€associated variable in predicting clinically relevant biochemical recurrence in ⟨scp⟩G⟨/scp⟩leason 7 prostate cancer. BJU International, 2013, 111, 921-927.	2.5	17
76	Molecular biomarkers for predicting outcomes in urothelial carcinoma of the bladder. Pathology, 2014, 46, 274-282.	0.6	17
77	Early perfusion MRI predicts survival outcome in patients with recurrent glioblastoma treated with bevacizumab and carboplatin. Journal of Neuro-Oncology, 2017, 131, 321-329.	2.9	17
78	Eve-3: A liver enriched suppressor of Ras/MAPK signaling. Journal of Hepatology, 2006, 44, 758-767.	3.7	16
79	Androgen deprivation therapy promotes an obesity-like microenvironment in periprostatic fat. Endocrine Connections, 2019, 8, 547-558.	1.9	16
80	Expression of ErbB-1 and 2 in vestibular schwannomas. Journal of Clinical Neuroscience, 2007, 14, 1199-1206.	1.5	15
81	Routinely reported †equivocal' lymphovascular invasion in prostatectomy specimens is associated with adverse outcomes. BJU International, 2017, 119, 567-572.	2.5	15
82	Ductal variant prostate carcinoma is associated with a significantly shorter metastasis-free survival. European Journal of Cancer, 2021, 148, 440-450.	2.8	13
83	Microscopic assessment of fresh prostate tumour specimens yields significantly increased rates of correctly annotated samples for downstream analysis. Pathology, 2012, 44, 204-208.	0.6	12
84	Loss of APKC expression independently predicts tumor recurrence in superficial bladder cancers. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 649-655.	1.6	11
85	Evaluation of models predicting insignificant prostate cancer to select men for active surveillance of prostate cancer. Prostate Cancer and Prostatic Diseases, 2015, 18, 137-143.	3.9	11
86	A study protocol for a phase II randomised, double-blind, placebo-controlled trial of sodium selenate as a disease-modifying treatment for behavioural variant frontotemporal dementia. BMJ Open, 2020, 10, e040100.	1.9	11
87	Toward precision immunotherapy using multiplex immunohistochemistry and in silico methods to define the tumor immune microenvironment. Cancer Immunology, Immunotherapy, 2021, 70, 1811-1820.	4.2	11
88	Reduction in expression of the benign AR transcriptome is a hallmark of localised prostate cancer progression. Oncotarget, 2016, 7, 31384-31392.	1.8	11
89	Circulating endothelial cells and progenitors: potential biomarkers of renal cell carcinoma. BJU International, 2010, 106, 1081-1087.	2.5	10
90	The Impact of Whole Genome Data on Therapeutic Decision-Making in Metastatic Prostate Cancer: A Retrospective Analysis. Cancers, 2020, 12, 1178.	3.7	10

#	Article	IF	CITATIONS
91	An epitope tagged mammalian/prokaryotic expression vector with positive selection of cloned inserts. Gene, 1997, 197, 337-341.	2.2	9
92	Loss of <i>SNAI2</i> in Prostate Cancer Correlates With Clinical Response to Androgen Deprivation Therapy. JCO Precision Oncology, 2021, 5, 1048-1059.	3.0	9
93	Interfering with cell-survival signalling as a treatment strategy for prostate cancer. BJU International, 2006, 97, 1149-1153.	2.5	8
94	Expression of ErbB-1 and ErbB-2 in meningioma. Journal of Clinical Neuroscience, 2010, 17, 1155-1158.	1.5	8
95	Percutaneous image-guided biopsy of prostate cancer metastases yields samples suitable for genomics and personalised oncology. Clinical and Experimental Metastasis, 2014, 31, 159-167.	3.3	8
96	Prostatic nerve subtypes independently predict biochemical recurrence in prostate cancer. Journal of Clinical Neuroscience, 2019, 63, 213-219.	1.5	8
97	Spred-2 steady-state levels are regulated by phosphorylation and Cbl-mediated ubiquitination. Biochemical and Biophysical Research Communications, 2006, 351, 1018-1023.	2.1	7
98	Sodium selenate as a disease-modifying treatment for mild–moderate Alzheimer's disease: an open-label extension study. BMJ Neurology Open, 2021, 3, e000223.	1.6	7
99	A phase 1b openâ€label study of sodium selenate as a diseaseâ€modifying treatment for possible behavioral variant frontotemporal dementia. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2022, 8, e12299.	3.7	7
100	Rapid screening of highly complex cDNA libraries using the polymerase chain reaction. Nucleic Acids Research, 1989, 17, 4415-4416.	14.5	6
101	Late biochemical recurrence after radical prostatectomy is associated with a slower rate of progression. BJU International, 2019, 123, 976-984.	2.5	6
102	Localization of two mouse genes encoding the protein tyrosine kinase receptor-related protein RYK. Mammalian Genome, 1995, 6, 255-256.	2.2	5
103	Potential use of circulating endothelial cells as a biomarker of renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2011, 29, 237-243.	1.6	5
104	Obesity suppresses tumor attributable PSA, affecting risk categorization. Endocrine-Related Cancer, 2018, 25, 561-568.	3.1	5
105	Developments in oligometastatic hormone-sensitive prostate cancer. World Journal of Urology, 2019, 37, 2549-2555.	2.2	5
106	Target Acquired: Progress and Promise of Targeted Therapeutics in the Treatment of Prostate Cancer. Current Cancer Drug Targets, 2015, 15, 394-405.	1.6	5
107	Bladder Cancer Biorepositories in the "-Omics―Era: Integrating Quality Tissue Specimens with Comprehensive Clinical Annotation. Biopreservation and Biobanking, 2013, 11, 166-172.	1.0	4
108	Tumor vascularity in prostate cancer: an update on circulating endothelial cells and platelets as noninvasive biomarkers. Biomarkers in Medicine, 2013, 7, 879-891.	1.4	4

#	Article	IF	CITATIONS
109	Preoperative biomarkers of tumour vascularity are elevated in patients with glioblastoma multiforme. Journal of Clinical Neuroscience, 2015, 22, 1802-1808.	1.5	4
110	MSH2-deficient prostate tumours have a distinct immune response and clinical outcome compared to MSH2-deficient colorectal or endometrial cancer. Prostate Cancer and Prostatic Diseases, 2021, 24, 1167-1180.	3.9	4
111	Sodium selenate as a disease-modifying treatment for progressive supranuclear palsy: protocol for a phase 2, randomised, double-blind, placebo-controlled trial. BMJ Open, 2021, 11, e055019.	1.9	4
112	Aurora kinase B is an independent protective factor in superficial bladder tumours with a dysfunctional G1 checkpoint. BJU International, 2008, 102, 247-252.	2.5	3
113	Transcriptome sequencing and multi-plex imaging of prostate cancer microenvironment reveals a dominant role for monocytic cells in progression. BMC Cancer, 2021, 21, 846.	2.6	3
114	The Prostate Cancer Immune Microenvironment, Biomarkers and Therapeutic Intervention. Uro, 2022, 2, 74-92.	0.8	3
115	Disrupting the Status Quo in Prostate Cancer Diagnosis. European Urology, 2017, 71, 193-194.	1.9	2
116	The modified International Society of Urological Pathology system improves concordance between biopsy and prostatectomy tumour grade. BJU International, 2021, , .	2.5	2
117	Identification and isolation of slow-cycling glioma stem cells. Methods in Cell Biology, 2022, , 21-30.	1.1	2
118	Reply: On the clinical relevance of circulating endothelial cells and platelets in prostate cancer. British Journal of Cancer, 2013, 108, 1388-1388.	6.4	1
119	Androstenedione Is the Preferred Androgen Source in Hormone Refractory Prostate Cancer—Response. Clinical Cancer Research, 2014, 20, 4972-4973.	7. O	1
120	Dual translation cassettes which allow prokaryotic and vertebrate protein expression from the same vector. Technical Tips Online, 1997, 2, 91-93.	0.2	0
121	Preparation of fluorescent in situ hybridisation probes without the need for optimisation of fragmentation. MethodsX, 2019, 6, 22-34.	1.6	0
122	Role of cell quiescence in glioblastoma cytotoxic resistance and strategies for therapeutic intervention., 2021,, 319-334.		0
123	Biomarkers of Response to Neoadjuvant Androgen Deprivation in Localised Prostate Cancer. Cancers, 2022, 14, 166.	3.7	0